Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**bifonazole + urea** is a topical combination drug used in the treatment of fungal nail infections (onychomycosis)[1][2][3]. It consists of bifonazole, an imidazole antifungal agent, and urea, a keratolytic agent that softens the nail plate. Bifonazole acts by inhibiting lanosterol 14-alpha demethylase, interfering with ergosterol synthesis required for fungal cell membrane integrity, leading to cell death[3]. Urea acts by breaking down keratin, allowing better penetration of bifonazole into the infected tissue[1][2]. The product is mainly indicated for non-traumatic topical treatment of onychomycoses, where urea facilitates painless removal of the affected nail, followed by antifungal elimination of the pathogen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bifonazole + urea.